United States Peptide Therapeutics (Retail Side) Market to Grow with a CAGR of 5.56% through 2030
Surge in
research and development activities is expected to drive the United States Peptide
Therapeutics (Retail Side) Market growth in the forecast period, 2026-2030.
According to
TechSci Research report, “United States Peptide Therapeutics (Retail Side)
Market – By Region, Competition, Forecast & Opportunities, 2030F”,
the United States Peptide Therapeutics (Retail Side) Market stood at USD 56.68
Billion in 2024 and is anticipated to grow with a CAGR of 5.56% through 2030. Initiatives
taken by government based on peptide therapeutics (retail side) has led to
favorable market conditions for the United States Peptide Therapeutics (Retail
Side) Market. Several factors contribute to the growth of various peptide therapeutics
(retail side) products.
The United
States government has implemented a range of initiatives aimed at fostering
growth, innovation, and accessibility within the peptide therapeutics market particularly
on the retail side, where consumer demand for advanced treatments continues to
rise. These initiatives are designed to promote the development, approval, and
distribution of peptide-based therapies, including high-demand categories such
as GLP-1 receptor agonists. The Food and Drug Administration (FDA) has
prioritized faster review pathways for peptide-based therapeutics that address
unmet medical needs, such as orphan drug designation, fast track, and
breakthrough therapy designations.
A surge in research and development (R&D) activities is a key driver accelerating the growth of the United States Peptide Therapeutics Market on the retail side. Pharmaceutical companies and biotech firms are investing heavily in the development of novel peptide-based drugs due to their high specificity, strong therapeutic efficacy, and generally favorable safety profiles. These efforts are expanding the pipeline of peptide therapeutics across a wide range of therapeutic areas, including metabolic disorders, oncology, immunology, and infectious diseases.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "United States Peptide Therapeutics (Retail Side) Market”
The United
States Peptide Therapeutics (Retail Side) Market is segmented into type,
indication, regional distribution, and company.
Based
on Type, Biosimilar Peptides have emerged as the dominating segment in the United
States Peptide Therapeutics (Retail Side) Market in 2024. This is due to their
cost-effectiveness, growing physician acceptance, and increasing demand for
affordable treatment alternatives. As the patents for several high-cost
innovative peptide drugs expire, biosimilar versions are entering the market at
competitive prices, making them more accessible to a broader patient
population. These products offer comparable safety, efficacy, and quality to
their branded counterparts, while significantly reducing the financial burden
on both healthcare providers and patients.
Based on Region,
Northeast have emerged as the fastest growing region in the United States Peptide
Therapeutics (Retail Side) Market in 2024. This is due to its strong healthcare
infrastructure, high concentration of leading academic medical centers, and a
population with greater access to advanced therapies. This region is home to
many top-tier hospitals and research institutions that are often early adopters
of cutting-edge treatments, including peptide-based therapeutics.
Major companies
operating in United States Peptide Therapeutics (Retail Side) Market are:
- CVS Health
- Walgreens Boots
Alliance, Inc.
- Walmart Pharmacy
- Rite Aid Corp
- The Kroger Co.
- Albertsons
- Costco Wholesale
Corporation
- Meijer, Inc.
- Hims & Hers
Health, Inc.
- Lemonaid Health,
Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“One of the most
impactful applications is the use of nanocarriers such as liposomes,
nanoparticles, and nanoemulsions to protect peptide molecules from premature
degradation and facilitate their targeted delivery. These nanocarrier systems
enhance the stability and absorption of peptides in the body, improving
bioavailability and enabling alternative routes of administration, including
oral and transdermal options, which are more convenient for patients compared
to traditional injectables”, said Mr. Karan Chechi, Research Director of
TechSci Research, a research-based management consulting firm.
“United States
Peptide Therapeutics (Retail Side) Market By Type (Innovative (Branded)
Peptides, Biosimilar Peptides, Generic Peptides, Others), By Indication (Type 2
Diabetes, Obesity/Weight Management, Neuroendocrine Tumors, Acromegaly, Growth
Hormone Deficiency, Others), By Region, Competition, Forecast &
Opportunities, 2020-2030F”, has evaluated the future growth potential of United
States Peptide Therapeutics (Retail Side) Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United States Peptide Therapeutics (Retail Side) Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com